{"name":"Merus N.V.","slug":"merus","ticker":"MRUS","exchange":"NASDAQ","domain":"merus.nl","description":"Merus N.V. is a clinical-stage oncology company focused on developing bispecific antibodies. The company's pipeline includes several promising candidates, including zenocutuzumab and zilucoplan. Merus has established a strong presence in the oncology market, with a growing portfolio of bispecific antibodies. The company's innovative approach to cancer treatment has generated significant interest among investors and clinicians.","hq":"Utrecht, Netherlands","founded":2010,"employees":"~350","ceo":"Bill Lundberg","sector":"Oncology / Bispecifics","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"1.3B","metrics":{"revenue":120000000,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2025-01-01","label":"Bizengri first approved","drug":"Bizengri","drugSlug":"zenocutuzumab","type":"approval","sentiment":"positive"},{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-12-31","label":"Bizengri PHASE2 readout","drug":"Bizengri","drugSlug":"zenocutuzumab","type":"phase3_readout","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2034-06-01","label":"zenocutuzumab patent cliff ($1.5B at risk)","drug":"zenocutuzumab","type":"patent_expiry","sentiment":"negative"},{"date":"2035-06-01","label":"zilucoplan patent cliff ($500M at risk)","drug":"zilucoplan","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"BIZENGRI","genericName":"ZENOCUTUZUMAB-ZBCO","slug":"zenocutuzumab-zbco","indication":"Other","status":"marketed"}]},{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"Bizengri","genericName":"ZENOCUTUZUMAB","slug":"zenocutuzumab","indication":"advanced unresectable or metastatic non-small cell lung cancer (NSCLC) harboring a neuregulin 1 (NRG1) gene fusion","status":"marketed"}]}],"pipeline":[{"name":"BIZENGRI","genericName":"ZENOCUTUZUMAB-ZBCO","slug":"zenocutuzumab-zbco","phase":"marketed","mechanism":"Zenocutuzumab-zbco binds to HER2 and HER3, inhibits their dimerization, and blocks NRG1 binding, reducing cell proliferation and signaling through the PI3K-AKT-mTOR pathway.","indications":[],"catalyst":""},{"name":"Bizengri","genericName":"ZENOCUTUZUMAB","slug":"zenocutuzumab","phase":"marketed","mechanism":"Bizengri works by binding to a specific protein on cancer cells to block their growth and spread.","indications":["advanced unresectable or metastatic non-small cell lung cancer (NSCLC) harboring a neuregulin 1 (NRG1) gene fusion","advanced unresectable or metastatic pancreatic adenocarcinoma harboring a neuregulin 1 (NRG1) gene fusion"],"catalyst":""}],"recentEvents":[{"date":"2024-02-27","type":"regulatory","headline":"Merus Announces FDA Acceptance of BLA for Zenocutuzumab","summary":"The FDA has accepted the Biologics License Application (BLA) for zenocutuzumab, a bispecific antibody targeting HER2 and EGFR, for the treatment of patients with HER2-positive breast cancer.","drugName":"zenocutuzumab","sentiment":"positive"},{"date":"2023-11-07","type":"earnings","headline":"Merus Reports Third Quarter 2023 Financial Results","summary":"Merus reported revenue of $13.4 million for the third quarter of 2023, a 25% increase from the same period in 2022.","drugName":"","sentiment":"neutral"},{"date":"2023-09-18","type":"deal","headline":"Merus Enters into Collaboration with Pfizer for Bispecific Antibodies","summary":"Merus has entered into a collaboration with Pfizer to develop and commercialize bispecific antibodies targeting various cancer indications.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMihgJBVV95cUxNWi1iSlVaSGVMMC16b3d5QVg5ZUJHOXY1YTFEVUYwN3lUTkl1eDNXVzRSYVpLSXpwSGgtSTZYV3RHaTVxM0x6dmhlQWJBRW0zVEE2X1dFdEpCTVlMaHUwdWllZmM3OEV2ZzlVbnJoODlhYkthVXJ1NVI5SUEzcG9ZNEtUbUZ6THpyUUptWklzUFQ3YmdpS3AzQTR1d0VXOHhSbzR3R3M4aFBQWkNGekowdHp0SHFONmdyOUNlSWwzc2U5UVQ0SFVtZlJCTDdmbVhhWEdLZFhTN3c2WWhwWWtoYzN1ZTA1U3Q3U3RTbVZ6Yk0zOUVUWjJQSl9GRVlWY1dpNFZxRFpB?oc=5","date":"2025-11-17","type":"deal","source":"PR Newswire","summary":"Merus and Halozyme Enter Global Collaboration and License Agreement to Develop Subcutaneous Formulation of Petosemtamab - PR Newswire","headline":"Merus and Halozyme Enter Global Collaboration and License Agreement to Develop Subcutaneous Formulation of Petosemtamab","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivAFBVV95cUxONmhLemlvcXNtTUxuRGV1dG16SEVmTmkwVWxUdF9sWTdXMzFkTEcwMUQzbmhuRk14N2k5WTZGMzNzRkVlU096YUdoOXRSUHMxeExET1FNSUMzbGZVc2w4MVFlVGFTckNWc29LV2s0M3djX0QzeEdBeTVRV0dwMXAyQXJmU2dPVUVHNkgzZHI0WjJpTU5PeHMyamNqSVp5OEZ5Q0tyaEdWd2dIN2ZDYmNndTBxeGxLc0xmTUpOSw?oc=5","date":"2025-10-06","type":"deal","source":"TradingView","summary":"GMAB Stock Soars 21.9% in a Month Following MRUS Acquisition Deal - TradingView","headline":"GMAB Stock Soars 21.9% in a Month Following MRUS Acquisition Deal","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuAFBVV95cUxOc3ZUSzZ0S1JURjNJMHIyamd6M1lmbEItdExfUVNVbl92UG5zb190dVpIVzVxc2NxTHcxeGJVTmVCOFBydEstaloteHI5QXU5c3cwX3NvZEdneEg4bk5FY2ZKeGVYVDhuajE2bnRJWXgyajU1WXU1R3FCenB3ZTVMOE94NEhGUVhCUWJIWHBIQ01oalJ5LTdpT1dKcklfLVNaYXpCN0lreDk2Vlh5WDIycmQtbkZ6Z1Bj?oc=5","date":"2025-09-29","type":"earnings","source":"Seeking Alpha","summary":"Genmab Buys Merus For $8bn: A Good Deal If Potential Is Converted Into Revenue (MRUS) - Seeking Alpha","headline":"Genmab Buys Merus For $8bn: A Good Deal If Potential Is Converted Into Revenue (MRUS)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigwFBVV95cUxOWVFGTzBFS2UzRVBINklQS1UtM00zNmR5OG1VczNmUm9WS0x6R0l5NmdxN3IxMlFPVF9admhMZDZxcUhSbXRhcGx6VzR1SmhmVlJTaDR3dFVocmdOYkV6LUpxUFA4OGFXRzhIdTBSTkZkX25QR2FUcTBPWWc0Y3c2UjN1Yw?oc=5","date":"2025-09-29","type":"deal","source":"The Business Journals","summary":"Cambridge-Netherlands cancer drug firm acquired for $8B - The Business Journals","headline":"Cambridge-Netherlands cancer drug firm acquired for $8B","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMic0FVX3lxTFBnRF9CYWxlY3JoOUFJVnl5aW1iNzQ0TTlvMjR2cjgtaGJqXzJ6LUhCWnRIcUw2bDN3dmtDOFZ5Z3hVdG5GQ0hZSVpmQWpJSkdHOFBmbTlEV0d6Rm0yRFh0NmVNM1lOUVV6TnJoMHJ1SlJyUGc?oc=5","date":"2025-06-29","type":"pipeline","source":"Seeking Alpha","summary":"Merus N.V.: Making Progress (NASDAQ:MRUS) - Seeking Alpha","headline":"Merus N.V.: Making Progress (NASDAQ:MRUS)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMidEFVX3lxTE5UbTdEV18tNFJrMEJ3VnpkV1djazZXcEppT2FNSktIcnhBYmpjYTc1ZUMwRS1MRW9XcFRFMm5EN3JsQUh4eVlicFFlbUEtM2prOWQ4a0pWZmpxc05jcmJQUXhtaFUwbGY1WV9fUlNEd1lscUZO?oc=5","date":"2025-05-09","type":"pipeline","source":"Yahoo Finance","summary":"Merus N.V. (MRUS): Among the Best Cancer Stocks to Invest in for Long-Term Gain - Yahoo Finance","headline":"Merus N.V. (MRUS): Among the Best Cancer Stocks to Invest in for Long-Term Gain","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTE1wcTBfbDRyNXZoNjQzSk1aUm5BTjhJUVNFRnVPMDFnZGlPSEpRb3RIWnNiOTFzWGl3N2NSS1N1Q0plR0hUcEl3eGdpUTc4ekRHMnVv?oc=5","date":"2025-04-24","type":"pipeline","source":"Stock Titan","summary":"MRUS Stock Price, News & Analysis - Stock Titan","headline":"MRUS Stock Price, News & Analysis","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijAJBVV95cUxPblg4ZjU5NWh3WHN4YzJjaHlTRy1PUklrWG1BRjBrSE8tT1NLSUF1eWs5ME1rR0xMek0tRXJnUTFNWXEtM0lGNHBwb0VIWVZzREhJR0JBTUU3QTgyNnVfWWpJb201aWF1eHlBdXAwd0F0eHd0TW1DUkNXT2dTWEZtd2p2VDlYSlRKX3N5dldiNjAxS0F1TGRYYXRSdWVZS0dSWXR0aGU2X0xKRzN2UVgwbVZPd1BhMURMWUQ3dTlqVkRrYk50VkxMRVdvWWtpM3MxMTIwSmctRlFPek8wUWxPaU80UHJBQUQ2NmJUeFB2UlVnQnk1SktQTUV5THZna1MtVVpqZEtxV2JnRjhU?oc=5","date":"2025-02-27","type":"earnings","source":"globenewswire.com","summary":"Merus Announces Financial Results for the Fourth Quarter and Full Year 2024 and Provides Business Update - globenewswire.com","headline":"Merus Announces Financial Results for the Fourth Quarter and Full Year 2024 and Provides Business Update","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiekFVX3lxTE9kXzJwWG9MTkJ0NjVaUnNxMVFySTdUQVgzY3pTU3FSTUtaT1JWU0cyN3VFTHRWT3c3WGs4RUdIaWFJZFlKUnpZdzg3ZFVyX3FkbmxON3BXRy1tekVsYnRpV0V1bkd6eWVEWUJmWlhZNFJiWlNtQi1YVVVR?oc=5","date":"2020-08-19","type":"pipeline","source":"marketscreener.com","summary":"Merus N.V.: Shareholders Board Members Managers and Company Profile | NL0011606264 - marketscreener.com","headline":"Merus N.V.: Shareholders Board Members Managers and Company Profile | NL0011606264","sentiment":"neutral"}],"patents":[{"drugName":"zenocutuzumab","drugSlug":"her2/egfr-bispecific-antibody","patentNumber":"","type":"Patent Cliff","expiryDate":"2034-06-01","territory":"US","annualRevenue":1500000000},{"drugName":"zilucoplan","drugSlug":"gm-csf-receptor-bispecific-antibody","patentNumber":"","type":"Patent Cliff","expiryDate":"2035-06-01","territory":"US","annualRevenue":500000000}],"drugCount":2,"phaseCounts":{"marketed":2},"enrichmentLevel":3,"visitCount":2,"keyCompetitors":["AstraZeneca","Roche Holding","Bristol Myers Squibb"],"therapeuticFocus":["Oncology","Autoimmune Diseases"],"financials":null,"yahoo":null}